ABL1 Knockout SK-HEP-1 Polyclonal Cells constitute a pool of SK-HEP-1 human liver adenocarcinoma cells carrying CRISPR/Cas9-mediated gene disruption at the ABL1 locus, generating a heterogeneous polyclonal loss-of-function model. This population-based knockout format avoids clonal artifacts and preserves biological variability inherent to the parental cell line, enabling robust assessment of ABL1-dependent signaling networks and therapeutic responses in a mixed genetic context.
The parental SK-HEP-1 cell line is an epithelial cell line derived from ascitic fluid of a patient with liver adenocarcinoma. It displays typical tumorigenic features, including anchorage-independent growth and invasive potential, making it a widely used model for hepatocellular carcinoma biology, metastatic progression, and drug sensitivity studies. The liver adenocarcinoma origin positions this knockout model uniquely for exploring ABL1 functions in hepatic tumorigenesis and the tumor microenvironment.
ABL1 is a non-receptor tyrosine kinase that integrates cues from cell surface receptors including PDGFR, EGFR, and integrins, and is directly activated by Src family kinases and ATM. Upon activation, ABL1 phosphorylates downstream effectors such as CRK, STAT5, JNK, and DOK1, and engages adaptor proteins GRB2 and SHC to propagate mitogenic and survival signals. ABL1 also interacts with CBL, 14-3-3 proteins, RIN1, and the amyloid precursor protein APP, modulating protein stability and subcellular localization. In the DNA damage response, ABL1 regulates p53 and the recombinase RAD51, linking genomic stability to kinase signaling. Additionally, ABL1 drives actin cytoskeleton rearrangement through the PAK-WAVE-ELMO axis, influencing cell adhesion and migration. The CRISPR-mediated gene disruption ablates these pleiotropic functions, yielding a comprehensive loss-of-function platform for dissecting ABL1-dependent pathways, including representative components BCR-ABL, Integrin ??1, CRKL, STAT5B, JUN, and TP53.
In the SK-HEP-1 hepatic tumor model, ABL1 knockout disrupts critical oncogenic signaling and adhesion programs, impairing cell proliferation, substrate attachment, and DNA repair capacity. This enables investigation of ABL1’s contribution to liver adenocarcinoma growth, invasion, and therapeutic resistance, particularly in the context of integrin-mediated signaling and the DNA damage response. The polyclonal knockout cells provide a tool to identify synergistic vulnerabilities to tyrosine kinase inhibitors and to characterize rewired signaling networks that may support tumor persistence in hepatic cancer.
Typical research applications include functional validation of ABL1 in liver cancer progression, screening of next-generation ABL1 inhibitors, drug resistance profiling, and dissection of kinase signaling cascades using phospho-tyrosine profiling and co-immunoprecipitation. The polyclonal knockout cells are amenable to proliferation (MTS/MTT) and colony formation assays, Transwell migration/invasion studies, apoptosis detection via Annexin V, and DNA damage response analyses. Gene disruption can be confirmed by Western blotting, RT-qPCR, and immunofluorescence. Researchers may leverage this model to validate ABL1 as a drug target and to explore combination therapies in hepatic adenocarcinoma. For further information or to request a detailed protocol, please contact Ascent Research.
